These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 28467490)
1. Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status. Mao K; Yang Y; Wu W; Liang S; Deng H; Liu J PLoS One; 2017; 12(5):e0176417. PubMed ID: 28467490 [TBL] [Abstract][Full Text] [Related]
2. Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ. Dania V; Liu Y; Ademuyiwa F; Weber JD; Colditz GA Breast Cancer Res; 2019 Nov; 21(1):120. PubMed ID: 31727116 [TBL] [Abstract][Full Text] [Related]
3. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. Wong SM; King T; Boileau JF; Barry WT; Golshan M Ann Surg Oncol; 2017 Sep; 24(9):2509-2517. PubMed ID: 28455673 [TBL] [Abstract][Full Text] [Related]
4. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. King TA; Pilewskie M; Muhsen S; Patil S; Mautner SK; Park A; Oskar S; Guerini-Rocco E; Boafo C; Gooch JC; De Brot M; Reis-Filho JS; Morrogh M; Andrade VP; Sakr RA; Morrow M J Clin Oncol; 2015 Nov; 33(33):3945-52. PubMed ID: 26371145 [TBL] [Abstract][Full Text] [Related]
5. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. Chuba PJ; Hamre MR; Yap J; Severson RK; Lucas D; Shamsa F; Aref A J Clin Oncol; 2005 Aug; 23(24):5534-41. PubMed ID: 16110014 [TBL] [Abstract][Full Text] [Related]
6. Is there a low-grade precursor pathway in breast cancer? King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747 [TBL] [Abstract][Full Text] [Related]
7. The Pathologic Finding of Combined Lobular Carcinoma Jean-Louis CJ; Masdon J; Smith B; Battles O; Dale P Am Surg; 2017 May; 83(5):482-485. PubMed ID: 28541858 [TBL] [Abstract][Full Text] [Related]
8. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Li CI; Malone KE; Saltzman BS; Daling JR Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564 [TBL] [Abstract][Full Text] [Related]
9. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. Miller ME; Muhsen S; Zabor EC; Flynn J; Olcese C; Giri D; Van Zee KJ; Pilewskie M Ann Surg Oncol; 2019 Dec; 26(13):4317-4325. PubMed ID: 31552614 [TBL] [Abstract][Full Text] [Related]
10. Risk of local failure in breast cancer patients with lobular carcinoma in situ at the final surgical margins: is re-excision necessary? Sadek BT; Shenouda MN; Abi Raad RF; Niemierko A; Keruakous AR; Goldberg SI; Taghian AG Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):726-30. PubMed ID: 24064317 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Coexisting Lobular Carcinoma In Situ With Invasive Lobular Carcinoma. Harbhajanka A; Lamzabi I; Syed S; Jain R; Ghai R; Reddy VB; Bitterman P; Gattuso P Appl Immunohistochem Mol Morphol; 2016; 24(10):738-743. PubMed ID: 26574630 [TBL] [Abstract][Full Text] [Related]
12. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Fisher ER; Costantino J; Fisher B; Palekar AS; Paik SM; Suarez CM; Wolmark N Cancer; 1996 Oct; 78(7):1403-16. PubMed ID: 8839545 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Goldstein NS; Kestin LL; Vicini FA Cancer; 2001 Aug; 92(4):738-47. PubMed ID: 11550142 [TBL] [Abstract][Full Text] [Related]
14. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ. Liu Y; West R; Weber JD; Colditz GA Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565 [TBL] [Abstract][Full Text] [Related]
15. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. De Brot M; Koslow Mautner S; Muhsen S; Andrade VP; Mamtani A; Murray M; Giri D; Sakr RA; Brogi E; King TA Breast Cancer Res Treat; 2017 Sep; 165(2):411-420. PubMed ID: 28612228 [TBL] [Abstract][Full Text] [Related]
16. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. Mullooly M; Khodr ZG; Dallal CM; Nyante SJ; Sherman ME; Falk R; Liao LM; Love J; Brinton LA; Gierach GL Am J Epidemiol; 2017 Dec; 186(12):1329-1340. PubMed ID: 28637226 [TBL] [Abstract][Full Text] [Related]
17. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR. Green AR; Young P; Krivinskas S; Rakha EA; Claire Paish E; Powe DG; Ellis IO Histopathology; 2009 Mar; 54(4):419-27. PubMed ID: 19309393 [TBL] [Abstract][Full Text] [Related]
18. Second primary breast cancer occurrence according to hormone receptor status. Kurian AW; McClure LA; John EM; Horn-Ross PL; Ford JM; Clarke CA J Natl Cancer Inst; 2009 Aug; 101(15):1058-65. PubMed ID: 19590058 [TBL] [Abstract][Full Text] [Related]
19. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Fisher ER; Land SR; Fisher B; Mamounas E; Gilarski L; Wolmark N Cancer; 2004 Jan; 100(2):238-44. PubMed ID: 14716756 [TBL] [Abstract][Full Text] [Related]
20. Current Concepts in Diagnosis, Molecular Features, and Management of Lobular Carcinoma In Situ of the Breast With a Discussion of Morphologic Variants. Ginter PS; D'Alfonso TM Arch Pathol Lab Med; 2017 Dec; 141(12):1668-1678. PubMed ID: 28574280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]